Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.52 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240330 | 1.00 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL1699647 | 1.00 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL14712700 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL8588339 | 0.92 | PYGM (0.56) | PYGMP2RY6P2RY14TK1DNPH1 | |
| SCHEMBL20072701 | 0.88 | TK2 (0.47) | PYGMTK2 | |
| SCHEMBL2614692 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL12240327 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL1699665 | 0.88 | PYGM (0.56) | PYGMP2RY6P2RY14DNPH1TK2 | |
| SCHEMBL26872396 | 0.81 | SLC28A1 (0.56) | P2RY6P2RY14 | |
| SCHEMBL15336921 | 0.81 | PYGM (0.61) | PYGMP2RY6P2RY14TK1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023383-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-02 | — | — | US | disclosed |
| US-20240066129-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20180209963-A1 | SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-07-26 | — | — | US | disclosed |
| US-20180104342-A1 | LIPID COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-19 | — | — | US | disclosed |
| US-9694077-B2 | Lipid compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9593335-B2 | Small interference RNAs, uses thereof and method for inhibiting the expression of PLK1 gene | Suzhou Ribo Life Science Co., Ltd. (CN) | 2017-03-14 | — | — | US | disclosed |
| US-9540682-B2 | Double-stranded nucleic acid, use and kit thereof in ribonuclease detection | Suzhou Ribo Life Science Co., Ltd. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20160289687-A1 | SMALL INTERFERENCE RNAS, USES THEREOF AND METHOD FOR INHIBITING THE EXPRESSION OF PLK1 GENE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2016-10-06 | — | — | US | disclosed |
| US-20160274089-A1 | SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2016-09-22 | — | — | US | disclosed |
| US-9394234-B2 | Lipid formulations | ARBUTUS BIOPHARMA CORPORATION (CA) | 2016-07-19 | — | — | US | disclosed |
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | Suzhou Ribo Life Science Co., Ltd. (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20120225434-A1 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120183602-A1 | LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120128760-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120101148-A1 | LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8158601-B2 | Lipid formulation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110097720-A1 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100324120-A1 | LIPID FORMULATION | BANK OF AMERICA, N.A. | 2010-12-23 | — | — | US | disclosed |
| US-20100222417-A1 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues | ALNYLAM PHARMACEUTICALS (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183602-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | PYGM 4343/4885P2RY6 3813/4885P2RY14 3785/4885 |
| US-20120101148-A1 | LIPID FORMULATION | SGMS1, SGMS2, NR1H2 | PYGM 4136/4885P2RY6 3297/4885P2RY14 3233/4885 |
| US-20100324120-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | PYGM 4343/4885P2RY6 3813/4885P2RY14 3785/4885 |
| US-20180104342-A1 | LIPID COMPOSITIONS | SGMS1, LIPA, SGMS2 | PYGM 4203/4885P2RY6 4598/4885P2RY14 4663/4885 |
| US-20100222417-A1 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues | RNASE1, MTREX, FABP2 | PYGM 2934/4885P2RY6 3884/4885P2RY14 4006/4885 |
| US-20130046006-A1 | INHIBITORS OF FAM3B GENE, INHIBITOR COMPOSITIONS, INHIBITING METHODS AND APPLICATIONS OF INHIBITORS IN PREPARING PHARMACEUTICALS | FAM222B, FAM162A, FAM20C | PYGM 2562/4885P2RY6 4840/4885P2RY14 4873/4885 |
| US-20120128760-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | PYGM 4222/4885P2RY6 4671/4885P2RY14 4716/4885 |
| US-20240066129-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | PYGM 4222/4885P2RY6 4671/4885P2RY14 4716/4885 |
| US-12023383-B2 | Lipid compositions | SGMS1, SGMS2, LIPA | PYGM 4222/4885P2RY6 4671/4885P2RY14 4716/4885 |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | PYGM 3715/4885P2RY6 4147/4885P2RY14 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.